AU643427B2
(en)
*
|
1988-10-31 |
1993-11-18 |
Immunex Corporation |
Interleukin-4 receptors
|
EP0419091A1
(en)
*
|
1989-09-07 |
1991-03-27 |
Schering Corporation |
Interleukin-4 receptors
|
ATE236249T1
(de)
|
1989-09-12 |
2003-04-15 |
Hoffmann La Roche |
Tfn-bindende proteine
|
CA2069090A1
(en)
*
|
1989-11-21 |
1991-05-22 |
John A. Hamilton |
Anti-inflammatory compositions and methods
|
US20030064480A1
(en)
*
|
1990-06-28 |
2003-04-03 |
Leander Lauffer |
Fusion proteins with immunoglobulin portions, the preparation and use thereof
|
US7253264B1
(en)
|
1990-06-28 |
2007-08-07 |
Sanofi-Arentideutschland GmbH |
Immunoglobulin fusion proteins, their production and use
|
US5453491A
(en)
*
|
1990-09-11 |
1995-09-26 |
Kiyoshi Takatsu |
Murine interleukin-5 receptor
|
US5770197A
(en)
*
|
1991-06-27 |
1998-06-23 |
Bristol-Myers Squibb Company |
Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
|
AU674292B2
(en)
*
|
1991-10-15 |
1996-12-19 |
Immunex Corporation |
Methods and compositions for treating allergic reactions
|
CA2124338A1
(en)
*
|
1991-11-27 |
1993-06-10 |
Nobuyuki Harada |
Region of cytoplasmic domain of the human interleukin-4 receptor, as antagonists of il-4
|
DE4322330A1
(de)
|
1992-08-31 |
1994-03-03 |
Behringwerke Ag |
Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen
|
US5714146A
(en)
*
|
1992-08-26 |
1998-02-03 |
Board Of Regents Of The University Of Washington |
IL-4 bone therapy
|
DE4228839A1
(de)
*
|
1992-08-29 |
1994-03-03 |
Behringwerke Ag |
Verfahren zum Nachweis und zur Bestimmung von Mediatoren
|
EP0604693A1
(en)
*
|
1992-12-29 |
1994-07-06 |
Schering-Plough |
Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
|
NZ263102A
(en)
*
|
1993-03-19 |
1997-05-26 |
Immunex Corp |
Pharmaceutical compositions comprising a ligand protein such as interleukin-4 and a soluble receptor protein that binds thereto
|
US5470952A
(en)
*
|
1993-10-20 |
1995-11-28 |
Regeneron Pharmaceuticals, Inc. |
CNTF and IL-6 antagonists
|
US5591825A
(en)
*
|
1994-07-05 |
1997-01-07 |
Tularik, Inc. |
Interleukin 4 signal transducers
|
US7091181B2
(en)
|
1994-12-12 |
2006-08-15 |
Omeros Corporation |
Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
|
US20020028798A1
(en)
*
|
1995-12-12 |
2002-03-07 |
Omeros Medical Systems |
Irrigation solution and method for inhibition of pain and inflammation
|
US5795966A
(en)
|
1995-02-22 |
1998-08-18 |
Immunex Corp |
Antagonists of interleukin-15
|
CA2225378C
(en)
|
1995-06-29 |
2012-04-17 |
Immunex Corporation |
Cytokine that induces apoptosis
|
US6541604B1
(en)
*
|
1996-01-08 |
2003-04-01 |
Genentech, Inc. |
Leptin receptor having a WSX motif
|
US7074397B1
(en)
*
|
1996-01-08 |
2006-07-11 |
Genentech, Inc. |
Method for enhancing proliferation or differentiation of a cell using ob protein
|
US20050019325A1
(en)
*
|
1996-01-08 |
2005-01-27 |
Carter Paul J. |
WSX receptor agonist antibodies
|
US5710023A
(en)
*
|
1996-03-01 |
1998-01-20 |
Genetics Institute, Inc. |
IL-13 cytokine receptor chain
|
US7078494B1
(en)
*
|
1996-03-01 |
2006-07-18 |
Genetics Institute, Llc |
Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
|
US20060205660A1
(en)
*
|
1996-06-20 |
2006-09-14 |
Sauvage Frederic D |
OB protein-immunoglobulin chimeras
|
US6586210B1
(en)
*
|
1996-08-23 |
2003-07-01 |
Human Genome Sciences, Inc. |
Polynucleotides encoding T1 receptor like ligand II
|
US6605271B2
(en)
|
1996-08-23 |
2003-08-12 |
Human Genome Sciences, Inc. |
T1 receptor-like ligand II and uses thereof
|
JP4138013B2
(ja)
|
1996-12-23 |
2008-08-20 |
イミュネックス・コーポレーション |
Tnfスーパーファミリーのメンバーであるnf−kappa bの受容体アクティベーターに対するリガンド
|
US6384203B1
(en)
|
1999-05-12 |
2002-05-07 |
Immunex Corporation |
Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
|
ES2316173T3
(es)
*
|
1997-10-29 |
2009-04-01 |
Genentech, Inc. |
Genes inducibles por wnt-1.
|
US6703488B1
(en)
*
|
1998-01-15 |
2004-03-09 |
Center For Molecular Medicine And Immunology |
Antibody/receptor targeting moiety for enhanced delivery of armed ligand
|
AU3065999A
(en)
*
|
1998-03-10 |
1999-09-27 |
Children's Hospital Of Philadelphia, The |
Compositions and methods for treatment of asthma
|
CA2340790C
(en)
|
1998-08-21 |
2012-07-10 |
Immunex Corporation |
Human il-1 epsilon dna and polypeptides
|
EP1939297A1
(en)
|
1998-09-24 |
2008-07-02 |
Pharmacia & Upjohn Company LLC |
Alzheimer's disease secretase
|
US6472179B2
(en)
|
1998-09-25 |
2002-10-29 |
Regeneron Pharmaceuticals, Inc. |
Receptor based antagonists and methods of making and using
|
US7067144B2
(en)
*
|
1998-10-20 |
2006-06-27 |
Omeros Corporation |
Compositions and methods for systemic inhibition of cartilage degradation
|
NZ512942A
(en)
|
1998-12-14 |
2004-01-30 |
Univ Johns Hopkins |
Polynucleotides encoding the IL-13 binding chains of the interleukin receptor, pharmaceutical compositions comprising the protein and methods of identifying inhibitors
|
US7553487B2
(en)
*
|
1998-12-14 |
2009-06-30 |
Genetics Institute, Llc |
Method and compositions for treating asthma
|
US20040220103A1
(en)
*
|
1999-04-19 |
2004-11-04 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
US20010021380A1
(en)
*
|
1999-04-19 |
2001-09-13 |
Pluenneke John D. |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
GB9912350D0
(en)
*
|
1999-05-26 |
1999-07-28 |
European Molecular Biology Lab Embl |
Modified cytokine
|
US6693172B1
(en)
|
1999-05-27 |
2004-02-17 |
Pharmacia And Upjohn Company |
Double mutant alpha-7 nicotinic acetylcholine receptor
|
US6455290B1
(en)
|
1999-07-09 |
2002-09-24 |
Pharmacia Italia S.P.A. |
Tankyrase homolog protein (THP), nucleic acids, and methods related to the same
|
AU2000263446A1
(en)
*
|
1999-07-13 |
2001-01-30 |
Genaissance Pharmaceuticals, Inc. |
Drug target isogenes: polymorphisms in the interleukin 4 receptor alpha gene
|
EP1222273A2
(en)
|
1999-10-22 |
2002-07-17 |
PHARMACIA & UPJOHN COMPANY |
Drosophila g protein coupled receptors, nucleic acids, and methods related to the same
|
WO2001042506A1
(en)
*
|
1999-12-10 |
2001-06-14 |
Human Genome Sciences, Inc. |
T1 receptor-like ligand ii and uses thereof
|
EP2298334A3
(en)
|
1999-12-20 |
2012-04-04 |
Immunex Corporation |
Tweak receptor
|
US6846486B1
(en)
*
|
2000-02-24 |
2005-01-25 |
Advanced Biotherapy Concepts, Inc. |
Method of treating allergy by administering an anti-histamine antibody
|
US6498026B2
(en)
|
2000-02-25 |
2002-12-24 |
Hercules Incorporated |
Variant galactose oxidase, nucleic acid encoding same, and methods of using same
|
AU2001259758A1
(en)
*
|
2000-05-12 |
2001-11-26 |
Immunex Corporation |
Interleukin-1 inhibitors in the treatment of diseases
|
EP1158058A1
(en)
*
|
2000-05-19 |
2001-11-28 |
Centre National De La Recherche Scientifique |
Compositions and methods suitable for nucleic acid analyses
|
WO2001090326A2
(en)
|
2000-05-22 |
2001-11-29 |
Pharmacia & Upjohn Company |
Novel matrix metalloproteinases
|
EP3190126A1
(en)
|
2000-05-26 |
2017-07-12 |
Immunex Corporation |
Use of interleukin-4 receptor (il-4r) antibodies and compositions thereof
|
US7259244B2
(en)
|
2000-06-16 |
2007-08-21 |
Nerviano Medical Sciences S.R.L. |
Human homologue of the DBF4/ASK1 protein, nucleic acids, and methods related to the same
|
US6686449B2
(en)
|
2000-06-30 |
2004-02-03 |
Pharmacia & Upjohn Company |
Mutant presenilin 1 polypeptides
|
US7067626B2
(en)
|
2000-07-05 |
2006-06-27 |
Pharmacia & Upjohn Company |
Human ion channel proteins
|
US20020076409A1
(en)
*
|
2000-07-12 |
2002-06-20 |
March Carl J. |
Method for treating cancer
|
US6652854B2
(en)
*
|
2000-08-08 |
2003-11-25 |
Immunex Corporation |
Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
|
AU2002241723A1
(en)
*
|
2000-12-21 |
2002-07-24 |
Inhale Therapeutic Systems, Inc. |
Storage stable powder compositions of interleukin-4 receptor
|
PL232477B1
(pl)
*
|
2001-09-20 |
2019-06-28 |
Immunex Corp |
System ekspresji gospodarza i sposób wytwarzania heteromerycznego kompleksu
|
DE60232742D1
(de)
|
2001-10-04 |
2009-08-06 |
Immunex Corp |
Ul16-bindungsprotein 4
|
US20050112616A1
(en)
*
|
2001-12-10 |
2005-05-26 |
William Lee |
Functionalized materials and libraries thereof
|
EP1497444B1
(en)
|
2002-03-27 |
2015-11-04 |
Immunex Corporation |
Methods for increasing polypeptide production
|
PT1408106E
(pt)
*
|
2002-10-11 |
2007-04-30 |
Sentoclone Ab |
Imunoterapia de cancro
|
AU2003285874A1
(en)
|
2002-10-16 |
2004-05-04 |
Amgen Inc. |
HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
|
ES2571355T3
(es)
|
2002-12-16 |
2016-05-24 |
Technion Res & Dev Foundation |
Sistema de cultivo sin células alimentadoras ni xenocontaminantes para células madre embrionarias humanas
|
AU2004207476A1
(en)
*
|
2003-01-18 |
2004-08-12 |
Children's Hospital Medical Center |
Regulation of allergen induced gene
|
EP1444989A1
(en)
*
|
2003-02-07 |
2004-08-11 |
Giorgio Dr. Stassi |
Sensitizing cells for apoptosis by selectively blocking cytokines
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
MXPA06000974A
(es)
|
2003-07-25 |
2006-08-31 |
Amgen Inc |
Antagonistas y agonistas de ldcam y metodos para su uso.
|
AU2004290017B2
(en)
|
2003-11-07 |
2012-05-03 |
Immunex Corporation |
Antibodies that bind interleukin-4 receptor
|
EP1697415A1
(en)
|
2003-11-12 |
2006-09-06 |
Biogen Idec MA Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
PT3718564T
(pt)
|
2003-12-23 |
2023-11-23 |
Genentech Inc |
Novos anticorpos anti-il 13 e suas utilizações
|
CA2554596A1
(en)
|
2004-02-27 |
2005-09-15 |
Regeneron Pharmaceuticals, Inc. |
Il-4/il-13 specific polypetides and therapeutic uses thereof
|
ATE465172T1
(de)
|
2004-03-05 |
2010-05-15 |
Univ Illinois |
Peptidträger für die verabreichung von arzneimitteln
|
US7582442B2
(en)
|
2004-03-16 |
2009-09-01 |
The Regents Of The University Of Michigan |
Methods and compositions for using aleveolar macrophage phospholipase A2
|
US7319015B2
(en)
|
2004-03-16 |
2008-01-15 |
The Regents Of The University Of Michigan |
Methods and compositions for using alveolar macrophage phospholipase A2
|
WO2005094879A2
(en)
*
|
2004-03-23 |
2005-10-13 |
Amgen, Inc. |
Monoclonal antibodies specific for human ox40l (cd 134l)
|
US7541158B2
(en)
|
2004-04-14 |
2009-06-02 |
Monell Chemical Senses Center |
Taste receptors of the T1R family from domestic dog
|
PL1742658T3
(pl)
|
2004-04-23 |
2015-05-29 |
Zoetis Services Llc |
Czynnik permisywności komórkowej wobec wirusów i jego zastosowania
|
US20090098142A1
(en)
*
|
2004-06-09 |
2009-04-16 |
Kasaian Marion T |
Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
|
AR049390A1
(es)
*
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
US7501121B2
(en)
*
|
2004-06-17 |
2009-03-10 |
Wyeth |
IL-13 binding agents
|
EP2311880A3
(en)
|
2005-01-05 |
2011-07-27 |
Biogen Idec MA Inc. |
Cripto binding molecules
|
CA2610839C
(en)
*
|
2005-06-14 |
2019-06-25 |
Amgen Inc. |
Self-buffering protein formulations
|
US20070009479A1
(en)
*
|
2005-06-17 |
2007-01-11 |
Aerovance, Inc. |
Methods for treating dermatitis using mutant human IL-4 compositions
|
KR20070009269A
(ko)
|
2005-07-15 |
2007-01-18 |
한국생명공학연구원 |
재조합단백질 생산용 단백질융합인자 라이브러리 및이로부터 획득된 단백질융합인자
|
JP2009516513A
(ja)
*
|
2005-11-21 |
2009-04-23 |
ラボラトワール セローノ ソシエテ アノニム |
ハイブリッド抗原結合分子の組成物及び製造方法並びにその使用
|
US8101173B2
(en)
*
|
2005-12-21 |
2012-01-24 |
Sentoclone International Ab |
Method for treating urinary bladder cancer
|
WO2007071390A1
(en)
*
|
2005-12-21 |
2007-06-28 |
Sentoclone Ab |
Method for treating malignant melanoma
|
JP5244610B2
(ja)
*
|
2005-12-21 |
2013-07-24 |
セントクローネ インターナショナル エービー |
ガン患者の免疫療法用腫瘍反応性tリンパ球の改良拡大法
|
WO2007071389A1
(en)
*
|
2005-12-21 |
2007-06-28 |
Sentoclone Ab |
Method for treating disseminated cancer
|
US8129334B2
(en)
|
2006-03-31 |
2012-03-06 |
The Regents Of The University Of California |
Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
|
AU2007263265A1
(en)
|
2006-06-21 |
2007-12-27 |
Apogenix Gmbh |
Differential IL-4 and/or IL-10 cytokine expression in human cancer
|
AU2007271349A1
(en)
*
|
2006-07-06 |
2008-01-10 |
Apogenix Gmbh |
Human IL-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy
|
JP5577543B2
(ja)
|
2006-09-08 |
2014-08-27 |
アムジエン・インコーポレーテツド |
Il−1ファミリーバリアント
|
TWI456062B
(zh)
|
2006-09-13 |
2014-10-11 |
Abbvie Inc |
細胞培養改良
|
EP2500415A1
(en)
|
2006-09-13 |
2012-09-19 |
Abbott Laboratories |
Cell culture improvements
|
CN101522716B
(zh)
|
2006-10-02 |
2013-03-20 |
瑞泽恩制药公司 |
抗人il-4受体的高亲和力人抗体
|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
US7833527B2
(en)
|
2006-10-02 |
2010-11-16 |
Amgen Inc. |
Methods of treating psoriasis using IL-17 Receptor A antibodies
|
US20080260820A1
(en)
*
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
JP2010527916A
(ja)
*
|
2007-04-23 |
2010-08-19 |
ワイス・エルエルシー |
Il−13関連障害を治療する方法および組成物ならびにその治療をモニターする方法
|
KR101770429B1
(ko)
|
2007-08-21 |
2017-08-22 |
암젠 인코퍼레이티드 |
인간 c-fms 항원 결합 단백질
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
EP2604628A3
(en)
*
|
2007-12-21 |
2013-08-21 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4R) - 173
|
US8092804B2
(en)
*
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
GB0803076D0
(en)
|
2008-02-20 |
2008-03-26 |
Univ Ghent |
Mucosal Membrane Receptor and uses thereof
|
WO2009134776A2
(en)
|
2008-04-29 |
2009-11-05 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
EP2113262B1
(en)
*
|
2008-04-29 |
2013-11-06 |
Proxy Biomedical Limited |
A Tissue Repair Implant
|
CA2725666A1
(en)
|
2008-06-03 |
2009-12-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
AU2009256250B2
(en)
|
2008-06-03 |
2013-05-30 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
WO2010002895A2
(en)
|
2008-06-30 |
2010-01-07 |
The Regents Of The University Of Michigan |
Lysosomal phospholipase a2 (lpla2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis
|
KR20110031369A
(ko)
|
2008-07-08 |
2011-03-25 |
아보트 러보러터리즈 |
프로스타글란딘 e2 이원 가변 도메인 면역글로불린 및 이의 용도
|
EP2364163B1
(en)
*
|
2008-07-18 |
2016-03-16 |
SentoClone International AB |
Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer
|
WO2010024927A2
(en)
|
2008-08-28 |
2010-03-04 |
The Research Foundation Of State University Of New York |
Treatment of amyloidoses using myelin basic protein and fragments thereof
|
KR101431091B1
(ko)
|
2008-12-04 |
2014-08-26 |
한국생명공학연구원 |
고분비성 단백질의 스크리닝 및 재조합 단백질의 생산을 위한 융합 파트너로서 그의 용도
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
WO2010133662A1
(en)
|
2009-05-20 |
2010-11-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of il-17 polypeptides for use in the prevention or treatment of atherosclerosis
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
US20120311728A1
(en)
|
2009-11-06 |
2012-12-06 |
Ziad Mallat |
Methods and pharmaceutical composition for the treatment of atherosclerosis
|
WO2011060242A2
(en)
|
2009-11-13 |
2011-05-19 |
Talecris Biotherapeutics, Inc. |
Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
EP2525806B1
(en)
|
2010-01-20 |
2014-06-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Angiopoietin-like-protein-4 (ANGPTL4) for the preservation of vascular endothelial-cell barrier integrity
|
WO2011127418A1
(en)
|
2010-04-09 |
2011-10-13 |
Amgen Inc. |
Btnl9 proteins, nucleic acids, and antibodies and uses thereof
|
CA2796055A1
(en)
|
2010-04-15 |
2011-10-20 |
Amgen Inc. |
Human fgf receptor and .beta.-klotho binding proteins
|
AU2011274423B2
(en)
|
2010-07-09 |
2016-02-11 |
Bioverativ Therapeutics Inc. |
Chimeric clotting factors
|
SG188190A1
(en)
|
2010-08-03 |
2013-04-30 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
US9012178B2
(en)
|
2010-08-05 |
2015-04-21 |
Amgen Inc. |
Dipeptides to enhance yield and viability from cell cultures
|
WO2012027570A2
(en)
|
2010-08-26 |
2012-03-01 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
EP2621511A1
(en)
|
2010-09-28 |
2013-08-07 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of bone density related diseases
|
US20140105898A1
(en)
|
2011-02-28 |
2014-04-17 |
Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo Garo |
Apoptosis-inducing molecules and uses therefor
|
CA2830254C
(en)
|
2011-03-16 |
2019-09-10 |
Amgen Inc. |
Fc variants
|
US9133493B2
(en)
|
2011-04-21 |
2015-09-15 |
Amgen Inc. |
Method for culturing mammalian cells to improve recombinant protein production
|
US20140086895A1
(en)
|
2011-05-10 |
2014-03-27 |
Universite De Rouen |
Methods and pharmaceutical compositions for the treatment of autoimmune diseases
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
EP2535714A1
(en)
*
|
2011-06-16 |
2012-12-19 |
Istituto Nazionale Di Genetica Molecolare-INGM |
Biomarkers for autoimmune liver diseases and uses thereof
|
PT2837680T
(pt)
|
2011-07-01 |
2020-04-17 |
Amgen Inc |
Cultura celular de mamífero
|
WO2013009971A1
(en)
|
2011-07-12 |
2013-01-17 |
E. I. Du Pont De Nemours And Company |
Detection and screening method and materials useful in performance thereof
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
WO2013016220A1
(en)
|
2011-07-22 |
2013-01-31 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
CN103917458A
(zh)
|
2011-09-02 |
2014-07-09 |
安姆根有限公司 |
药物产品和分析药物产品的光暴露的方法
|
AU2012312274B2
(en)
|
2011-09-22 |
2017-11-16 |
Amgen Inc. |
CD27L antigen binding proteins
|
WO2013050441A1
(en)
|
2011-10-05 |
2013-04-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
|
EP2596802A1
(en)
|
2011-11-23 |
2013-05-29 |
PLS-Design GmbH |
Pharmaceutical composition for treatment of allergic reactions
|
EP2785365B1
(en)
|
2011-11-28 |
2017-07-19 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Pharmaceutical composition for use in the treatment of dysfunction associated with aging
|
AU2012347540A1
(en)
|
2011-12-08 |
2014-06-26 |
Amgen Inc. |
Agonistic human LCAT antigen binding proteins and their use in therapy
|
AR089231A1
(es)
|
2011-12-15 |
2014-08-06 |
Amgen Inc |
Metodo de floculacion
|
EP2797955A2
(en)
|
2011-12-30 |
2014-11-05 |
AbbVie Inc. |
Dual variable domain immunoglobulins against il-13 and/or il-17
|
EA201491346A1
(ru)
|
2012-01-10 |
2014-11-28 |
Байоджен Айдек Ма Инк. |
Усиление транспорта терапевтических молекул через гематоэнцефалический барьер
|
SI2841456T1
(sl)
|
2012-04-27 |
2018-10-30 |
Novo Nordisk A/S |
Antigen-vezavni proteini liganda človeškega CD30
|
JO3623B1
(ar)
|
2012-05-18 |
2020-08-27 |
Amgen Inc |
البروتينات المرتبطة بمولد المستضاد st2
|
EP3434276A1
(en)
|
2012-06-06 |
2019-01-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment of cancer
|
EP2674168A1
(en)
|
2012-06-14 |
2013-12-18 |
PLS-Design GmbH |
Modulation of effector T cell responses by local depletion of complement component C3
|
US20150166630A1
(en)
|
2012-07-19 |
2015-06-18 |
Amgen Inc. |
Btnl3 proteins, nucleic acids, and antibodies and uses thereof
|
KR102502640B1
(ko)
|
2012-08-21 |
2023-02-23 |
사노피 바이오테크놀로지 |
Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
|
US9309318B2
(en)
|
2012-10-17 |
2016-04-12 |
Amgen, Inc. |
Compositions relating to anti-IL-21 receptor antibodies
|
MY171664A
(en)
|
2012-11-01 |
2019-10-22 |
Abbvie Inc |
Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
JP6518192B2
(ja)
|
2012-12-07 |
2019-05-22 |
ノースカロライナ ステート ユニバーシティーNorth Carolina State University |
ベータ−ヘキソシルトランスフェラーゼ及びその使用
|
WO2014109858A1
(en)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
US10023608B1
(en)
|
2013-03-13 |
2018-07-17 |
Amgen Inc. |
Protein purification methods to remove impurities
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
TWI625390B
(zh)
|
2013-03-14 |
2018-06-01 |
安美基公司 |
用於增加重組蛋白質之甘露糖含量之方法
|
US20140271629A1
(en)
|
2013-03-14 |
2014-09-18 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
SI3395423T1
(sl)
|
2013-03-14 |
2023-12-29 |
Amgen Inc. |
Odstranjevanje izluženega liganda za afinitetno čiščenje
|
MX2015013181A
(es)
|
2013-03-15 |
2015-12-11 |
Amgen Inc |
Anticuerpos humanos pac1.
|
WO2014144817A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Inhibitory polypeptides specific to wnt inhibitors
|
US10588949B2
(en)
|
2013-03-15 |
2020-03-17 |
Bioverativ Therapeutics Inc. |
Factor IX polypeptide formulations
|
BR112015023797A2
(pt)
|
2013-03-15 |
2017-10-24 |
Abbvie Inc |
proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
|
EP2970483A2
(en)
|
2013-03-15 |
2016-01-20 |
Amgen Inc. |
Methods and compositions relating to anti-ccr7 antigen binding proteins
|
WO2014144553A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
|
US9481901B2
(en)
|
2013-05-30 |
2016-11-01 |
Amgen Inc. |
Methods for increasing mannose content of recombinant proteins
|
ES2895824T3
(es)
|
2013-05-30 |
2022-02-22 |
Kiniksa Pharmaceuticals Ltd |
Proteínas de enlace al antígeno del receptor de oncastatina M
|
TWI697334B
(zh)
|
2013-06-04 |
2020-07-01 |
美商再生元醫藥公司 |
藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
|
WO2014205365A1
(en)
|
2013-06-21 |
2014-12-24 |
Sanofi |
Methods for treating nasal polyposis by administering an il-4r antagonist
|
TWI634900B
(zh)
|
2013-07-11 |
2018-09-11 |
再生元醫藥公司 |
藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
AU2014318017B2
(en)
|
2013-09-05 |
2020-02-06 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
CN105722992B
(zh)
|
2013-09-13 |
2021-04-20 |
豪夫迈·罗氏有限公司 |
用于检测和定量细胞系和重组多肽产物中的宿主细胞蛋白的组合物和方法
|
EP3043820A4
(en)
|
2013-09-13 |
2017-07-12 |
F. Hoffmann-La Roche AG |
Methods and compositions comprising purified recombinant polypeptides
|
US20160257748A1
(en)
|
2013-09-25 |
2016-09-08 |
Amgen Inc. |
V-c-fc-v-c antibody
|
JP6621744B2
(ja)
|
2013-10-31 |
2019-12-18 |
アムジエン・インコーポレーテツド |
組換えタンパク質のグリコシル化を調節するためのモネンシンの使用
|
WO2015086727A2
(en)
|
2013-12-11 |
2015-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New prognostic method for patients suffering of a cancer
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
CN106029896B
(zh)
|
2014-01-13 |
2020-10-27 |
美国安进公司 |
调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量
|
US10106829B2
(en)
|
2014-01-29 |
2018-10-23 |
Amgen Inc. |
Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
AU2014380174B2
(en)
|
2014-01-29 |
2018-08-30 |
Amgen Inc. |
Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
CA3177696A1
(en)
|
2014-02-20 |
2015-08-27 |
Allergan, Inc. |
Complement component c5 antibodies
|
JP6673840B2
(ja)
|
2014-02-21 |
2020-03-25 |
サノフィ・バイオテクノロジー |
Il−4r拮抗薬の投与により喘息を処置または予防するための方法
|
CN110724691A
(zh)
|
2014-02-27 |
2020-01-24 |
阿勒根公司 |
补体因子Bb抗体
|
JP6526037B2
(ja)
|
2014-02-28 |
2019-06-05 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
Il−4rアンタゴニストを投与することによる皮膚感染を処置するための方法
|
NO2785538T3
(da)
|
2014-05-07 |
2018-08-04 |
|
|
EP3143404B1
(en)
|
2014-05-16 |
2018-08-29 |
Amgen Inc. |
Assay for detecting th1 and th2 cell populations
|
SG10202113019XA
(en)
|
2014-06-04 |
2021-12-30 |
Amgen Inc |
Methods for harvesting mammalian cell cultures
|
WO2016023916A1
(en)
|
2014-08-12 |
2016-02-18 |
Kymab Limited |
Treatment of disease using ligand binding to targets of interest
|
MX2017003247A
(es)
|
2014-09-15 |
2017-11-30 |
Amgen Inc |
Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
|
WO2016071701A1
(en)
|
2014-11-07 |
2016-05-12 |
Kymab Limited |
Treatment of disease using ligand binding to targets of interest
|
IL303337A
(en)
|
2014-11-14 |
2023-08-01 |
Regeneron Pharma |
Methods for the treatment of chronic sinusitis with nasal polyps by adding an R4–IL antagonist
|
MX2017006463A
(es)
|
2014-11-19 |
2018-04-20 |
Amgen Inc |
Cuantificacion de porcion de glicano en glicoproteinas recombinantes.
|
BR112017011652A2
(pt)
|
2014-12-01 |
2018-06-26 |
Amgen Inc. |
processo para manipulação do nível de teor de glicano de uma glicoproteína
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
AU2016215155A1
(en)
|
2015-02-04 |
2017-08-17 |
F. Hoffmann-La Roche Ag |
Tau antisense oligomers and uses thereof
|
CN115181778A
(zh)
|
2015-02-04 |
2022-10-14 |
百时美施贵宝公司 |
选择治疗性分子的方法
|
EP3273981B1
(en)
|
2015-03-24 |
2020-04-29 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Method and pharmaceutical composition for use in the treatment of diabetes
|
JP6938383B2
(ja)
|
2015-04-02 |
2021-09-22 |
インターベット インターナショナル ベー. フェー. |
イヌインターロイキン4受容体アルファに対する抗体
|
JOP20200116A1
(ar)
|
2015-04-24 |
2017-06-16 |
Amgen Inc |
طرق لعلاج أو الوقاية من الصداع النصفي
|
EP3286227A2
(en)
|
2015-04-24 |
2018-02-28 |
F. Hoffmann-La Roche AG |
Multispecific antigen-binding proteins
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
WO2017049004A1
(en)
|
2015-09-15 |
2017-03-23 |
Amgen Inc. |
Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
|
EP3353288A1
(en)
|
2015-09-22 |
2018-08-01 |
H. Hoffnabb-La Roche Ag |
Expression of fc-containing proteins
|
CN108431026B
(zh)
|
2015-11-02 |
2023-02-17 |
豪夫迈·罗氏有限公司 |
制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法
|
WO2017106578A1
(en)
|
2015-12-15 |
2017-06-22 |
Amgen Inc. |
Pacap antibodies and uses thereof
|
UA127495C2
(uk)
|
2015-12-23 |
2023-09-13 |
Амджен Інк. |
Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить
|
CN115073581A
(zh)
|
2016-05-04 |
2022-09-20 |
美国安进公司 |
用于扩增t调节性细胞的白细胞介素-2突变蛋白
|
AU2017298984B2
(en)
|
2016-07-22 |
2023-08-31 |
Amgen Inc. |
Methods of purifying Fc-containing proteins
|
KR20220151021A
(ko)
|
2016-09-01 |
2022-11-11 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
|
US20180110856A1
(en)
|
2016-10-21 |
2018-04-26 |
Amgen Inc. |
Pharmaceutical Formulations and Methods of Making the Same
|
AU2017356317A1
(en)
|
2016-11-14 |
2019-05-30 |
Amgen Inc. |
Bispecific or biparatopic antigen binding proteins and uses thereof
|
TWI784988B
(zh)
|
2016-12-01 |
2022-12-01 |
美商再生元醫藥公司 |
治療發炎症狀的方法
|
EA039807B1
(ru)
|
2017-01-06 |
2022-03-16 |
ЭйБиЭл БИО ИНК. |
Антитело к -синуклеину и его применение
|
CA3049110A1
(en)
|
2017-01-06 |
2018-07-12 |
Abl Bio Inc. |
Anti-.alpha.-syn antibody and use thereof
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
US20200131518A1
(en)
|
2017-03-14 |
2020-04-30 |
Amgen Inc. |
Control of total afucosylated glycoforms of antibodies produced in cell culture
|
JOP20190248A1
(ar)
|
2017-04-21 |
2019-10-20 |
Amgen Inc |
بروتينات ربط مولد ضد trem2 واستخداماته
|
BR112019021812A2
(pt)
|
2017-04-21 |
2020-05-26 |
Kindred Biosciences, Inc. |
Molécula receptora de il4/il13 para uso veterinário
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
WO2018237097A1
(en)
|
2017-06-20 |
2018-12-27 |
Amgen Inc. |
METHOD OF TREATING OR REDUCING METABOLIC DISORDERS USING GASTRIC INHIBITING PEPTIDE RECEPTOR BINDING PROTEINS (GIPR) IN ASSOCIATION WITH GLP-1 AGONISTS
|
US20210228738A1
(en)
|
2017-07-17 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
|
WO2019020480A1
(en)
|
2017-07-24 |
2019-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
|
US11053309B2
(en)
|
2017-08-04 |
2021-07-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating active eosinophilic esophagitis
|
WO2019028382A1
(en)
|
2017-08-04 |
2019-02-07 |
Amgen Inc. |
CYS-MABS CONJUGATION METHOD
|
PT3515465T
(pt)
|
2017-08-18 |
2024-03-04 |
Regeneron Pharma |
Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
|
AU2018359219A1
(en)
|
2017-10-30 |
2020-04-23 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating or preventing asthma by administering an IL-4R antagonist
|
EP3737699A1
(en)
|
2018-01-12 |
2020-11-18 |
Amgen Inc. |
Pac1 antibodies and uses thereof
|
MA52186A
(fr)
|
2018-03-26 |
2021-02-17 |
Amgen Inc |
Glycoformes afucosylées totales d'anticorps produits en culture cellulaire
|
CN112153982A
(zh)
|
2018-05-13 |
2020-12-29 |
瑞泽恩制药公司 |
用于通过施用il-4r抑制剂治疗特应性皮炎的方法
|
WO2019225787A1
(ko)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
JP2022502454A
(ja)
|
2018-10-04 |
2022-01-11 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
認知機能を回復又は改善するための方法
|
CN111057721B
(zh)
*
|
2018-10-12 |
2021-03-16 |
百奥赛图(北京)医药科技股份有限公司 |
人源化IL-4和/或IL-4Rα改造动物模型的制备方法及应用
|
WO2020123327A1
(en)
|
2018-12-10 |
2020-06-18 |
Amgen Inc. |
Mutated piggybac transposase
|
CN113597328A
(zh)
|
2019-03-21 |
2021-11-02 |
瑞泽恩制药公司 |
用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
|
CA3141690A1
(en)
|
2019-05-30 |
2020-12-03 |
Amgen Inc. |
Engineering the hinge region to drive antibody dimerization
|
JP2022538232A
(ja)
|
2019-06-28 |
2022-09-01 |
アムジエン・インコーポレーテツド |
抗cgrp受容体/抗pac1受容体二重特異性抗原結合タンパク質
|
BR112022000581A2
(pt)
|
2019-08-05 |
2022-03-03 |
Regeneron Pharma |
Métodos para tratamento de alergia e intensificação de imunoterapia específica dos alergénos através da administração de um antagonista de il-4r
|
AU2020328038A1
(en)
|
2019-08-13 |
2022-03-31 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
MX2022003461A
(es)
|
2019-09-26 |
2022-04-19 |
Amgen Inc |
Metodos de produccion de composiciones de anticuerpos.
|
TW202132340A
(zh)
|
2019-11-04 |
2021-09-01 |
美商安進公司 |
治療白血病之方法
|
JP2022553813A
(ja)
|
2019-11-08 |
2022-12-26 |
アムジエン・インコーポレーテツド |
ヘテロIgG分子の対合のための電荷対変異の操作
|
EP4061838A1
(en)
|
2019-11-19 |
2022-09-28 |
Amgen Inc. |
Novel multispecific antibody format
|
CR20220341A
(es)
|
2019-12-17 |
2022-08-19 |
Amgen Inc |
Agonista doble de interleucina-2/receptor de tnf para uso en terapia
|
CA3164129A1
(en)
|
2019-12-20 |
2021-06-24 |
Amgen Inc. |
Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
|
WO2021247892A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Assessment of cleaning procedures of a biotherapeutic manufacturing process
|
MX2023002125A
(es)
|
2020-08-20 |
2023-04-26 |
Amgen Inc |
Proteínas de unión a antígenos con disulfuro no canónico en la región fab.
|
US20230374162A1
(en)
|
2020-10-07 |
2023-11-23 |
Amgen Inc. |
Rational selection of building blocks for the assembly of multispecific antibodies
|
CA3197930A1
(en)
|
2020-10-15 |
2022-04-21 |
Amgen Inc. |
Relative unpaired glycans in antibody production methods
|
TW202233660A
(zh)
|
2020-10-30 |
2022-09-01 |
美商安進公司 |
過表現胰島素樣生長因子受體突變體以調節igf補充
|
JP2023548595A
(ja)
|
2020-11-10 |
2023-11-17 |
アムジエン・インコーポレーテツド |
多重特異性抗原結合ドメインの新規のリンカー
|
CA3216559A1
(en)
|
2021-04-20 |
2022-10-27 |
Amgen Inc. |
Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
|
EP4330281A1
(en)
|
2021-04-29 |
2024-03-06 |
Amgen Inc. |
Methods for reducing low molecular weight species of recombinantly-produced proteins
|
CA3222409A1
(en)
|
2021-06-07 |
2022-12-15 |
Amgen Inc. |
Using fucosidase to control afucosylation level of glycosylated proteins
|
AU2022289721A1
(en)
|
2021-06-10 |
2024-01-04 |
Amgen Inc. |
Engineered nrg-1 variants with improved selectivity toward erbb4 but not against erbb3
|
TW202328442A
(zh)
|
2021-09-10 |
2023-07-16 |
美商安進公司 |
平臺宿主對igf—培養基之適應
|
CA3233279A1
(en)
|
2021-10-05 |
2023-04-13 |
Amgen Inc. |
Fc-gamma receptor ii binding and glycan content
|
CA3241882A1
(en)
|
2021-12-29 |
2023-07-06 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|
WO2023172965A1
(en)
|
2022-03-09 |
2023-09-14 |
Amgen Inc. |
Optimized transfection protocol
|
WO2023175022A1
(en)
|
2022-03-16 |
2023-09-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to treat infectious diseases
|
WO2023215267A1
(en)
|
2022-05-02 |
2023-11-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-interleukin-4 receptor (il-4r) antibody formulations
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
TW202409060A
(zh)
|
2022-05-02 |
2024-03-01 |
美商再生元醫藥公司 |
用於降低脂酶活性之方法
|
EP4406973A1
(en)
|
2023-01-27 |
2024-07-31 |
Fundació Privada Institut de Recerca de la SIDA-Caixa |
Antibodies and uses thereof for the treatment of infections caused by enveloped viruses
|